8158 On Other Exchanges
8158 is not on other exchanges.

china regenerative medicine (8158) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHINA REGENERATIVE MEDICINE (8158)

Related News

No related news articles were found.

china regenerative medicine (8158) Related Businessweek News

No Related Businessweek News Found

china regenerative medicine (8158) Details

China Regenerative Medicine International Limited, an investment holding company, researches and develops bio-medical and healthcare products, and medical techniques. It operates through three segments: Tissue Engineering, Stem Cell, and Cosmetics and Healthcare. The company offers ActivSkin, a tissue-engineered skin product; Acellular Corneal Stroma for use in therapeutic lamellar keratoplasty; Calcined Bovine Bone, a protein-detracted bone substitute material for inducing natural bone regeneration; and Acellular Anal Fistula Repair Stroma for anal fistula disease. It also researches and develops Recombinant Human Acellular Dermal Matrix, which is targeted on and applied for second degree burns; Selective Acellular Skin for use as a wound dressing; Acellular Amniotic Membrane, an anti-adhesion agent for muscle and tender rebuilding operations; and Absorbable Dental Membrane for jawbone defect restoration, which are in Stage II business development process. In addition, the company provides Cell Sheet-Autologous Chondrocyte Implantation, a medical technique for repairing knee and other related cartilage damages; and produces and sells cellular and stem cell therapy products. Further, it develops various cosmetic and skin care products for anti-aging, whitening, spot removal, and other applications on skin revival under the ascara brand, as well as anti-aging and healthcare solutions, and anti-aging and other natural supplement products. Additionally, it offers contract research organization services of drug screening, drug efficacy, and toxicity assays in the pre-clinical drug development; and produces and distributes 3D perfusion bioreactors and related consumables. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Wanchai, Hong Kong.

542 Employees
Last Reported Date: 07/27/17
Founded in 1995

china regenerative medicine (8158) Top Compensated Officers

Executive Director
Total Annual Compensation: $150.0K
Vice Chairman & Compliance Officer
Total Annual Compensation: $1.4M
Compensation as of Fiscal Year 2017.
china regenerative medicine
China Regenerative Medicine International Limited Reports Audited Consolidated Cash Flow Results for the Year Ended April 30, 2017

China Regenerative Medicine International Limited reported audited consolidated cash flow results for the year ended April 30, 2017. For the year, the company reported net cash used in operating activities of HKD 460,893,000 compared to HKD 99,117,000 a year ago. Purchase of property, plant and equipment was HKD 70,947,000 compared to HKD 16,348,000 a year ago. Purchase of other intangible assets was HKD 2,576,000 compared to HKD 4,021,000 a year ago.

China Regenerative Medicine International Limited Announces Audited Consolidated Earnings Results for the Year Ended April 30, 2017

China Regenerative Medicine International Limited announced audited consolidated earnings results for the year ended April 30, 2017. For the year, the company reported revenue of HKD 356,987,000 against HKD 27,751,000 a year ago. loss before income tax was HKD 210,920,000 against HKD 191,198,000 a year ago. loss for the period attributable to owners of the company was HKD 184,502,000 or 1.049 cents per basic share against HKD 190,902,000 or 1.103 cents per basic share a year ago. The overall increase in revenue was attributable to an increase in revenue across different segments, including tissue engineering, stem cell, cosmetics and others and medical equipment.

China Regenerative Medicine International Limited to Report Fiscal Year 2017 Final Results on Jul 17, 2017

China Regenerative Medicine International Limited announced that they will report fiscal year 2017 final results on Jul 17, 2017


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

8158 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8158.
View Industry Companies

Industry Analysis


Industry Average

Valuation 8158 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.2x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.4x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA REGENERATIVE MEDICINE, please visit www.crmi.hk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.